Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate
详细信息 查看全文
- 作者：Denholm ; Elizabeth M. ; Cauchon ; Elizabeth ; Poulin ; Catherine ; Silver ; Paul J.
- 关键词：Dermatan ; Chondroitin sulfate ; Fibroblast ; Proliferation ; Chondroitinase
- 刊名：European Journal of Pharmacology
- 出版年：2000
- 出版时间：July 21, 2000
- 年：2000
- 卷：400
- 期：2-3
- 页码：145-153
- 全文大小：392 K
文摘
In the current study, a glycosaminoglycan lyase, chondroitinase B, was used to study the role of dermatan sulfate proteoglycans on human dermal fibroblast proliferation. Pretreatment with chondroitinase B significantly decreased fibroblast proliferative responses to serum (20 % to 55 % ). In contrast, heparinase III and chondroitinase AC were less effective in inhibiting fibroblast proliferation to serum. Analysis of glycosaminoglycans on chondroitinase B-treated fibroblasts confirmed that dermatan sulfate was removed from fibroblasts by this enzyme. Chondroitinase B treatment also decreased proliferation to basic fibroblast growth factor (bFGF) by 20 % and reduced receptor binding by 25 % . Heparinase III inhibited bFGF binding by 73 % , but decreased proliferation to bFGF by only 21 % . Chondroitinase AC had no effect on bFGF proliferation or binding. These data suggest that dermatan sulfate proteoglycans play a significant role in the control of human dermal fibroblast proliferation.